190 related articles for article (PubMed ID: 31589795)
1. Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity.
Sinha N; Chowdhury S; Sarkar RR
Proteins; 2020 Mar; 88(3):514-526. PubMed ID: 31589795
[TBL] [Abstract][Full Text] [Related]
2. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
Zhang H; Sun Z; Liu Z; Song C
Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
[TBL] [Abstract][Full Text] [Related]
3. Analysis of vismodegib resistance in D473G and W535L mutants of SMO receptor and design of novel drug derivatives using molecular dynamics simulations.
Liao S; Floyd C; Verratti N; Leung L; Wu C
Life Sci; 2020 Mar; 244():117302. PubMed ID: 31953165
[TBL] [Abstract][Full Text] [Related]
4. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.
Pricl S; Cortelazzi B; Dal Col V; Marson D; Laurini E; Fermeglia M; Licitra L; Pilotti S; Bossi P; Perrone F
Mol Oncol; 2015 Feb; 9(2):389-97. PubMed ID: 25306392
[TBL] [Abstract][Full Text] [Related]
5. Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant.
Shimizu Y; Ishii T; Ogawa K; Sasaki S; Matsui H; Nakayama M
Eur J Pharmacol; 2015 Oct; 764():220-227. PubMed ID: 26048307
[TBL] [Abstract][Full Text] [Related]
6. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.
Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H
Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104
[TBL] [Abstract][Full Text] [Related]
7. Deciphering structural stability and binding mechanisms of potential antagonists with smoothened protein.
Sinha N; Chowdhury S; Sarkar RR
J Biomol Struct Dyn; 2018 Aug; 36(11):2917-2937. PubMed ID: 28849750
[TBL] [Abstract][Full Text] [Related]
8. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
Danial C; Sarin KY; Oro AE; Chang AL
Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
[TBL] [Abstract][Full Text] [Related]
9. Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
Atwood SX; Sarin KY; Whitson RJ; Li JR; Kim G; Rezaee M; Ally MS; Kim J; Yao C; Chang AL; Oro AE; Tang JY
Cancer Cell; 2015 Mar; 27(3):342-53. PubMed ID: 25759020
[TBL] [Abstract][Full Text] [Related]
10. A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
Buetti-Dinh A; Jensen R; Friedman R
BMC Cancer; 2018 May; 18(1):569. PubMed ID: 29776351
[TBL] [Abstract][Full Text] [Related]
11. Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
Tian N; Wu H; Zhang H; Yang D; Lv L; Yang Z; Zhang T; Quan D; Zhou L; Xie Y; Xu Y; Wei N; Zhang J; Chen M; Schmitz JC; Tian Y; Wu S
Bioorg Med Chem; 2020 Aug; 28(16):115584. PubMed ID: 32690258
[TBL] [Abstract][Full Text] [Related]
12. Identification of Novel Smoothened Ligands Using Structure-Based Docking.
Lacroix C; Fish I; Torosyan H; Parathaman P; Irwin JJ; Shoichet BK; Angers S
PLoS One; 2016; 11(8):e0160365. PubMed ID: 27490099
[TBL] [Abstract][Full Text] [Related]
13. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
14. Triazoles bind the C-terminal domain of SMO: Illustration by docking and molecular dynamics simulations the binding between SMO and triazoles.
Liu M; Liang G; Zheng H; Zheng N; Ge H; Liu W
Life Sci; 2019 Jan; 217():222-228. PubMed ID: 30543826
[TBL] [Abstract][Full Text] [Related]
15. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
Yauch RL; Dijkgraaf GJ; Alicke B; Januario T; Ahn CP; Holcomb T; Pujara K; Stinson J; Callahan CA; Tang T; Bazan JF; Kan Z; Seshagiri S; Hann CL; Gould SE; Low JA; Rudin CM; de Sauvage FJ
Science; 2009 Oct; 326(5952):572-4. PubMed ID: 19726788
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling study on resistance of WT/D473H SMO to antagonists LDE-225 and LEQ-506.
Tu J; Li JJ; Song LT; Zhai HL; Wang J; Zhang XY
Pharmacol Res; 2018 Mar; 129():491-499. PubMed ID: 29175550
[TBL] [Abstract][Full Text] [Related]
17. Design and biological evaluation of phenyl imidazole analogs as hedgehog signaling pathway inhibitors.
Sun C; Zhang Y; Wang H; Yin Z; Wu L; Huang Y; Zhang W; Wang Y; Hu Q
Chem Biol Drug Des; 2021 Mar; 97(3):546-552. PubMed ID: 32946174
[TBL] [Abstract][Full Text] [Related]
18. State of the art of Smo antagonists for cancer therapy: advances in the target receptor and new ligand structures.
Espinosa-Bustos C; Mella J; Soto-Delgado J; Salas CO
Future Med Chem; 2019 Mar; 11(6):617-638. PubMed ID: 30912670
[TBL] [Abstract][Full Text] [Related]
19. ABT-199 inhibits Hedgehog pathway by acting as a competitive inhibitor of oxysterol, rather as a BH3 mimetic.
Wang J; Zhang Y; Huang WJ; Yang J; Tang WG; Huang TM; Tan WF
Acta Pharmacol Sin; 2021 Jun; 42(6):1005-1013. PubMed ID: 32855528
[TBL] [Abstract][Full Text] [Related]
20. Structural optimization on a virtual screening hit of smoothened receptor.
Song S; Jiang J; Zhao L; Wang Q; Lu W; Zheng C; Zhang J; Ma H; Tian S; Zheng J; Luo L; Li Y; Yang ZJ; Zhang X
Eur J Med Chem; 2019 Jun; 172():1-15. PubMed ID: 30939349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
